Omeros to buy Nura in cash/stock deal

Two privately held Seattle-based biotechs--Omeros and Nura--are combining in a cash/stock buyout. Omeros' acquisition will add Nura's work in schizophrenia and Parkinson's disease. Omeros' lead product is being developed to improve joint function. The three investors in Nura--Arch, Aravis and Novartis--are making an unspecified but "large" investment in Omeros. That money is part of a $53 million venture round that Omeros says it will announce soon. Omeros' CEO Gregory Demopulos has also been discussing his intentions to take the 12-year-old biotech public next year--market conditions permitting.

- see the report on the buyout from the Seattle Post Intelligencer

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.